sacituzumab govitecan
gilead sciences
['bcsm', 'neostar', 'sacituzumab', 'brca']
neostar trial : sacituzumab neoadjuvant with pcr 30%, notably higher in patients with gbrca1/2pv (75%) #bcsm #asco22 
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine